Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 27, 2010

View Archived Issues

Scientists design PIE-12-trimer that specifically inhibits HIV entry into host cells

Phase I data presented on hypnotic agent GF-015535-00

Interim phase I/II data suggest safety of everolimus in advanced HCC

Novartis reports on clinical development of LDE-225

BI-10773 improves glycemic control in large study in type 2 diabetes

Phico Therapeutics details phase I tolerability of PT1.2

Immatics raises funds to advance cancer vaccine portfolio

NasVax begins phase IIa trial of oral anti-CD3 immunotherapy

University of Kansas claims new HSP 90 inhibitors

Pro-Pharmaceuticals and Numoda collaborate on phase III Davanat trial

FDA and EMA to review vandetanib for advanced medullary thyroid cancer

AnGes receives fast track status for Collategene in critical limb ischemia

Santaris Pharma to initiate phase IIa trial of miravirsen in hepatitis C

Dynavax begins phase Ib study of its universal flu vaccine candidate

GSK to use biomarker from OncoMethylome in immunotherapy program

S*BIO obtains funding to support clinical programs

DiagnoCure files PMA application with FDA for Progensa PCA3 assay

RXi and EyeGate Pharma collaborate on ocular drug delivery system

Abbott and Reata to codevelop bardoxolone methyl for CKD

New dual GLP-1/glucagon receptor agonists described

FDA orphan drug status for darinaparsin in peripheral T-cell lymphoma

Vifor and Kissei Pharma partner to develop and market PA-21 in Japan

European orphan status granted to rFVIIIFc in hemophilia A

OP Bio Factory and Nagoya University disclose new beta-NGF enhancers

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...